MDACC Study No:2013-0190 ( NCT No: NCT01952249)
Title:A Phase 1b/2 Study of Demcizumab plus Paclitaxel in Subjects with Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Principal Investigator:Robert Coleman
Treatment Agent:Demcizumab; Paclitaxel; Placebo
Study Status:Open
Study Description:This clinical research study is made up of 2 phases: Phase 1b and Phase 2.
Phase 1a has already been completed. Its goal was to find the highest
tolerable dose of demcizumab when given by itself.

The goal of Phase 1b of this study is to learn the highest tolerable dose of
demcizumab that can be given in combination with paclitaxel.

The goal of Phase 2 of this study is to learn if the combination of demcizumab
and paclitaxel can help control ovarian, peritoneal, or fallopian tube cancer.
To do this, researchers will compare demcizumab to a placebo. A placebo is not
a drug. It looks like the study drug but is not designed to treat any disease
or illness. It is designed to be compared with a study drug to learn if the
study drug has any real effect.

The safety of the drug combination will be studied in both phases.
Hide details for General InformationGeneral Information

Disease Group:Fallopian Tube; Ovary
Phase of Study:Phase I/Phase II
Treatment Agents:Demcizumab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:OncoMed Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Coleman
For Clinical Trial Enrollment:713-745-3357
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults